The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Homephototherapy.jpg



FA info icon.svg Angle down icon.svg Medical equipment data
Health topic Child mortality
Health classification Treatment


FA info icon.svg Angle down icon.svg Project data
Location Iran
Status Commercialized
Made No
Replicated No
OKH Manifest Download

Problem being addressed

Jaundice in newborns is an extremely common condition that can result in kernicterus (brain damage) or even death without medical treatment. Resource-limited areas often lack the equipment necessary to treat this condition with phototherapy. In addition, phototherapy systems are generally large so they cannot be transported, causing newborns to extend their stay in hospitals.

Detailed description of the solution

The home phototherapy unit is a small, portable device that can treat jaundice in newborns at home. The light waves transform toxic bilirubin in the newborn’s blood into a safer product. This unit has a timer, cooling system, an alarm, four folding legs. It is transportable and can be easily used by any caregiver.

Designed by

  • Designed by: Ehsan Dargazy
  • Manufacturer: Tosan Co.
  • Manufacturer location: Iran

When and where it was tested/implemented

Iran

References

Other internally generated reports

Tosan Co. (2012). Home Phototherapy 027. Retrieved November 29, 2013 from here.

Externally generated reports

Design to Improve Life. Home Phototherapy. Retrieved November 29, 2013 from here.

Maternova. (January 11, 2013). Home Phototherapy Unit. Retrieved November 29, 2013 from here.

IP and copyright

Copyright © 2012 Tosan Co.

FA info icon.svg Angle down icon.svg Page data
Part of Global Health Medical Device Compendium
SDG SDG03 Good health and well-being
Authors Kelly Wojcik
License CC-BY-SA-3.0
Language English (en)
Related 0 subpages, 1 pages link here
Impact 250 page views
Created November 30, 2013 by Kelly Wojcik
Modified May 2, 2022 by Felipe Schenone
Cookies help us deliver our services. By using our services, you agree to our use of cookies.